Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Haddad

Showing results (661-670 of 698) with videos related to

Pageof 70
Sort By:
Cancer|April 7, 2025
Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trialHannah Goulart, Hagop Kantarjian, Gautam Borthakur, et al.
Brain Research|June 12, 2024
Alzheimer's-linked axonal changes accompany elevated antidromic action potential failure rate in aged miceMatthew L Russo, Gelique Ayala, Demetria Neal, et al.
The Lancet. Haematology|September 20, 2024
Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trialNicholas J Short, Daniel Nguyen, Elias Jabbour, et al.
American Journal of Hematology|May 15, 2023
Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1Nicholas J Short, Elias Jabbour, Walid Macaron, et al.
Cancer|April 9, 2024
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemiaElias Jabbour, Fadi G Haddad, Koji Sasaki, et al.
American Journal of Hematology|January 5, 2023
Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up resultsHagop Kantarjian, Nicholas J Short, Nitin Jain, et al.
American Journal of Hematology|January 23, 2023
The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitorsElias J Jabbour, Koji Sasaki, Fadi G Haddad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 19, 2024
Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALLHagop Kantarjian, Nicholas J Short, Fadi G Haddad, et al.
American Journal of Hematology|December 24, 2024
Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic DesignationJayastu Senapati, Hagop M Kantarjian, Fadi G Haddad, et al.
Annales De Cardiologie Et D'Angeiologie|September 23, 2019
[An independent observatory in Vendée on ST-elevated acute myocardial infarction (the OVISCA Register). A Departmental evaluation of demographic trends, mortality and delays before treatment]E Boiffard, J Dimet, O Baron, et al.
Pageof 70

Showing results (661-670 of 698) with videos related to

Sort By:
Pageof 70
Cancer|April 7, 2025
Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trialHannah Goulart, Hagop Kantarjian, Gautam Borthakur, et al.
Brain Research|June 12, 2024
Alzheimer's-linked axonal changes accompany elevated antidromic action potential failure rate in aged miceMatthew L Russo, Gelique Ayala, Demetria Neal, et al.
The Lancet. Haematology|September 20, 2024
Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trialNicholas J Short, Daniel Nguyen, Elias Jabbour, et al.
American Journal of Hematology|May 15, 2023
Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1Nicholas J Short, Elias Jabbour, Walid Macaron, et al.
Cancer|April 9, 2024
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemiaElias Jabbour, Fadi G Haddad, Koji Sasaki, et al.
American Journal of Hematology|January 5, 2023
Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up resultsHagop Kantarjian, Nicholas J Short, Nitin Jain, et al.
American Journal of Hematology|January 23, 2023
The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitorsElias J Jabbour, Koji Sasaki, Fadi G Haddad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 19, 2024
Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALLHagop Kantarjian, Nicholas J Short, Fadi G Haddad, et al.
American Journal of Hematology|December 24, 2024
Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic DesignationJayastu Senapati, Hagop M Kantarjian, Fadi G Haddad, et al.
Annales De Cardiologie Et D'Angeiologie|September 23, 2019
[An independent observatory in Vendée on ST-elevated acute myocardial infarction (the OVISCA Register). A Departmental evaluation of demographic trends, mortality and delays before treatment]E Boiffard, J Dimet, O Baron, et al.
Pageof 70